The CE Mark approval for On-X AAP allows its distribution in the European Union. Credit: CryoLife

Cardiac and vascular surgery company CryoLife has secured CE Mark for its On-X Ascending Aortic Prosthesis (AAP), enabling resumed distribution of the device in the EU.

On-X AAP is intended to treat damaged (or rectify the malfunctioning of) native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm. Aortic root diseases co-exist in almost as much as 10% of all aortic valve replacements.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CryoLife chairman, president, and CEO Pat Mackin said: “The absence of the On-X AAP from the market since late 2016 has hindered our ability to compete for certain mechanical valve tenders in the EU.

“With the receipt of the CE Mark on the AAP, we once again have a complete portfolio of On-X products available in Europe, allowing us to be more competitive and potentially drive market share gains in the mechanical valve market.

“The On-X AAP offers the best hemodynamics of any commercially available valved conduit device, and we will resume selling the On-X AAP in the EU immediately.”

The device is a part of CryoLife’s On-X Heart Valve portfolio that consists of On-X Aortic Valve and ON-X Mitral Valve among other prosthetic heart valves.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

On-X Aortic Valve by CryoLife is claimed to be the first mechanical aortic heart valve to secure both FDA and CE Mark approval for its use with a reduced warfarin dosage based on PROACT trial results.

Trial results indicated over 60% reduction in bleeding events without complete risk of stroke.

Enrolment for On-X Mitral Valve’s PROACT (Lowered INR Mitral Arm) prospective randomised clinical trial is currently being performed.

The study is seeking a reduced warfarin indication similar to that of the On-X Aortic Valve.

Headquartered in Georgia, CryoLife manufactures and distributes medical devices, as well as implantable tissues for cardiac and vascular surgical procedures that focus on aortic repair.